ClinicalTrials.gg
RecruitingNCT07810010Updated Oct 19, 2026

Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older

A Phase 2 interventional study of Bivalent RSV+HMPV protein vaccine and Placebo in Respiratory Syncytial Virus, Human Metapneumovirus and Healthy Volunteers, sponsored by Sanofi. Recruiting at 21 sites in 2 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Sanofi · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 19, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8,000
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy, safety, and immunogenicity of a single IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate.

The study will include a Safety Lead-in Cohort that will be enrolled first and will comprise 200 participants aged 60 years and older randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo (100 participants per arm).

The enrollment of the Main Cohort will start after the completion of the ESDR (Early Safety Data Review), pending a positive outcome. For the Main Cohort, 7800 participants (3900 participants per arm) will be randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo.

02

Conditions studied

  • Respiratory Syncytial Virus
  • Human Metapneumovirus
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older on the day of inclusion
  • Participants who, as determined by medical evaluation including medical history, physical examination, and clinical judgment of the Investigator are eligible for inclusion

Exclusion criteria

Exclusion Criteria:

  • Known/suspected immunodeficiency; therapy/immunomodulators in past 6 months; long-term systemic (eg, prednisone for more than 2 weeks in past 3 months); history of immune-mediated neurological disease. Of note, persons living with stable are not excluded
  • Known systemic to any of the study intervention components or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Previous history of Guillain-Barré Syndrome (GBS)
  • Previous vaccination against RSV and/or HMPV (with a licensed or vaccine either as a monovalent vaccine or any combination of the antigens) or previous receipt of RSV and/or HMPV monoclonal antibody

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,000 participants (estimated)

Study arms

  • Experimental
    Safety Lead-in Cohort - Experimental

    Single administration of IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate

    Biological: Bivalent RSV+HMPV protein vaccine

  • Placebo comparator
    Safety Lead-in Cohort - Placebo

    Single administration of matching placebo

    Biological: Placebo

  • Experimental
    Main Cohort - Experimental

    Single administration of IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate

    Biological: Bivalent RSV+HMPV protein vaccine

  • Placebo comparator
    Main Cohort - Placebo

    Single administration of matching placebo

    Biological: Placebo

Interventions

  • BiologicalBivalent RSV+HMPV protein vaccine

    IM injection

    Also known as: RPF08203

  • BiologicalPlacebo

    IM injection

06

What researchers measure

Primary outcomes

  1. Occurrence of the first episode of RSV-LRTD (Lower Respiratory Tract Disease)

    Time frame: From 14 days to 12 months after vaccination

  2. Occurrence of the first episode of HMPV-LRTD

    Time frame: From 14 days to 12 months after vaccination

Secondary outcomes

  1. Occurrence of the first episode of RSV-LRTD and/or HMPV-LRTD

    Time frame: From 14 days to 12 months after vaccination

  2. Occurrence of the first episode of RSV-ARD (Acute Respiratory Disease) and/or HMPV-ARD

    Time frame: From 14 days to 12 months after vaccination

  3. Occurrence of the first episode of severe RSV-LRTD and/or severe HMPV-LRTD

    Time frame: From 14 days to 12 months after vaccination

  4. Occurrence of the first episode of RSV-URTD and/or HMPV-URTD

    Time frame: From 14 days to 12 months after vaccination

  5. RSV A, RSV B, and HMPV A, HMPV B serum nAb titers in a subset of participants

    Time frame: At pre-vaccination and 8 days, 28 days, 6 months and 12 months post- vaccination

  6. Presence of immediate unsolicited systemic AEs (Adverse Events)

    Time frame: Within 30 minutes after vaccination

  7. Presence of solicited injection site and systemic reactions in a subset of participants

    Time frame: Up to 7 days after vaccination

  8. Presence of unsolicited AEs reported

    Time frame: Up to 27 days after vaccination

  9. Presence of MAAEs (Medically Attended Adverse Events)

    Time frame: Within 6 months after vaccination

  10. Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Event of Special Interest)

    Time frame: Within 6 months after vaccination

  11. Presence of related SAEs, related AESIs, and fatal SAEs

    Time frame: Up to 12 months post-vaccination

  12. Presence of out-of-range biological test results in a subset of participants

    Time frame: 7 days after vaccination

07

Study locations

21 of 21 sites recruiting
  • Investigational Site Number : 0360008
    Bruse, Australian Capital Territory 2617, Australia
    Recruiting
  • Investigational Site Number : 0360006
    Blacktown, New South Wales 2148, Australia
    Recruiting
  • Investigational Site Number : 0360007
    Maroubra, New South Wales 2035, Australia
    Recruiting
  • Investigational Site Number : 0360002
    Albion, Queensland 4010, Australia
    Recruiting
  • Investigational Site Number : 0360003
    Sippy Downs, Queensland 4556, Australia
    Recruiting
  • Investigational Site Number : 0360009
    Melbourne, Victoria 3124, Australia
    Recruiting
  • Investigational Site Number : 8260012
    Cardiff, Cardiff [Caerdydd Gb-crd] CF15 9SS, United Kingdom
    Recruiting
  • Investigational Site Number : 8261010
    Bournemouth, Dorset BH7 7DW, United Kingdom
    Recruiting
  • Investigational Site Number : 8263010
    Dorchester, Dorset DT1 2JY, United Kingdom
    Recruiting
  • Investigational Site Number : 8260013
    London, England E1 2AX, United Kingdom
    Recruiting
  • Investigational Site Number : 8260011
    London, England SW10 9NH, United Kingdom
    Recruiting
  • Investigational Site Number : 8262010
    Portsmouth, Hampshire PO6 3LY, United Kingdom
    Recruiting
  • Investigational Site Number : 8260002
    Blackpool, Lancashire FY3 7EN, United Kingdom
    Recruiting
  • Investigational Site Number : 8260007
    London, London, City of NW10 2PB, United Kingdom
    Recruiting
  • Investigational Site Number : 8260001
    Corby, Northamptonshire NN17 2UN, United Kingdom
    Recruiting
  • Investigational Site Number : 8260005
    Witney, Oxfordshire OX28 6JS, United Kingdom
    Recruiting
  • Investigational Site Number : 8260009
    Bromborough, Wirral CH62 6EE, United Kingdom
    Recruiting
  • Investigational Site Number : 8260006
    West Kirby, Wirral CH48 5AA, United Kingdom
    Recruiting
  • Investigational Site Number : 8260003
    Bradford, BD9 6DA, United Kingdom
    Recruiting
  • Investigational Site Number : 8260004
    London, SW10 0LR, United Kingdom
    Recruiting
  • Investigational Site Number : 8260008
    Stockton-on-Tees, TS19 8PE, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 9, 2026
StartActual
Sep 9, 2026
Primary completionEst.
Jul 3, 2028
CompletionEst.
Jul 5, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (5 United Kingdom)
  • Investigational Site Number : 8260013 · London, United Kingdom
  • Investigational Site Number : 8260001 · Corby, United Kingdom
  • Investigational Site Number : 8260009 · Bromborough, United Kingdom
  • Investigational Site Number : 8260003 · Bradford, United Kingdom
  • Investigational Site Number : 8260008 · Stockton-on-Tees, United Kingdom
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    5 sites added
    Show 5 added (5 United Kingdom)
    • Investigational Site Number : 8260013 · London, United Kingdom
    • Investigational Site Number : 8260001 · Corby, United Kingdom
    • Investigational Site Number : 8260009 · Bromborough, United Kingdom
    • Investigational Site Number : 8260003 · Bradford, United Kingdom
    • Investigational Site Number : 8260008 · Stockton-on-Tees, United Kingdom
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07810010
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Sep 9, 2026
Primary completion
Jul 3, 2028 (estimated)
Completion
Jul 5, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion